Welcome to our dedicated page for Repare Therapeutics SEC filings (Ticker: RPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Repare Therapeutics’ SEC paperwork is packed with dense clinical data, synthetic lethality science, and cash-burn figures that can overwhelm even seasoned biotech analysts. If you have ever asked, “How do I read Repare Therapeutics’ annual report 10-K?” or hunted for “Repare Therapeutics insider trading Form 4 transactions,” you know the challenge.
Stock Titan solves this complexity. Our AI-powered summaries translate 300-page disclosures into clear takeaways, flagging trial milestones, collaboration revenue, and liquidity runways. Get real-time alerts the moment a “Repare Therapeutics Form 4 insider transactions real-time” filing hits EDGAR, review a “Repare Therapeutics quarterly earnings report 10-Q filing” with side-by-side metric trends, or skim the newest 8-K material events explained without scrolling through legal boilerplate.
Every document type is here—10-K, 10-Q, 8-K, S-8, DEF 14A proxy statements, plus
- “Repare Therapeutics executive stock transactions Form 4” for sentiment shifts
- “Repare Therapeutics earnings report filing analysis” to compare R&D expenses
- “Repare Therapeutics proxy statement executive compensation” to evaluate incentive alignment
Repare Therapeutics Inc. (Nasdaq: RPTX) filed a Form 8-K to disclose changes approved by its Compensation Committee on June 13, 2025 to the severance package of Michael Zinda, Ph.D., Executive Vice President & Chief Scientific Officer.
Under the amended terms, if Dr. Zinda is terminated without “cause” or resigns for “good reason,” and the separation is not in connection with a change-in-control, he will receive:
- Lump-sum cash equal to nine months of current base salary.
- COBRA premiums paid by Repare for up to 12 months post-separation.
- Accelerated vesting of all unvested equity awards for nine months from the separation date.
- Pro-rated target bonus for the year of separation, paid in a lump sum.
If a change in control occurs within 90 days after the separation date, Dr. Zinda will instead receive the enhanced change-in-control severance stipulated in Section 5.7(c) of his previously disclosed Employment Agreement. All other existing severance protections in that agreement remain unchanged.
The disclosure is limited to executive compensation; no financial results, operational updates, or strategic transactions were reported.
FAQ
What is the current stock price of Repare Therapeutics (RPTX)?
What is the market cap of Repare Therapeutics (RPTX)?
What is the core focus of Repare Therapeutics Inc?
How does the company discover new therapeutic targets?
What is meant by synthetic lethality?
How does Repare Therapeutics integrate technology in its approach?
What competitive advantages does the company offer?
How is precision medicine reflected in their research?
Who are the key collaborators and investors supporting the company?
What role does clinical informatics play in their process?
